⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PSNL News
Personalis, Inc. Common Stock
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
businesswire.com
PSNL
Personalis to Participate in the Piper Sandler 37 th Annual Healthcare Conference
businesswire.com
PSNL
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
businesswire.com
PSNL